Yuto Takeuchi

TL;DR: In this article, the analytical and clinical performance of QuickNavi™-COVID19 Ag, a newly developed antigen test in Japan, was evaluated using a prospective observational study at a PCR center between October 7 and December 5, 2020.

TL;DR: In this paper, a prospective study in a drive-through testing site located at a PCR center was conducted to evaluate the diagnostic performance of the antigen test QuickNavi-COVID19 Ag using anterior nasal samples and to compare the degrees of coughs or sneezes induction and the severity of pain between anterior nasal collection and nasopharyngeal collection.

TL;DR: In this article, the authors evaluated the diagnostic performance of Quick Chaser® Auto SARS-CoV-2, a novel digital immunochromatographic assay that is expected to have higher sensitivity than conventional antigen tests.

TL;DR: In this article, the authors evaluated the analytical performance of the newly developed rapid molecular assays GENECUBE® HQ SARS-CoV-2 (SARS CoV2) and GENE® FLU A/B (A/B) for detecting severe acute respiratory syndrome coronavirus 2.

TL;DR: The QuickNavi™-COVID19 Ag showed lower sensitivity for the asymptomatic group than for symptomatic patients as mentioned in this paper, but its specificity was consistently high, and no false positives were found in this study.